The Conflict of Interest Bill introduced in the Rajya Sabha is a welcome step to control the grey areas in which “public private partnerships” are conducted. AMONG the many things that have proliferated in the economic boom of the brash new India is conflict of interest. So widespread, comprehensive and many-tentacled has this feature become that it is often no longer even recognised to exist, much less to be a...

The World of Work 2012 report presents a bleak picture of the global job situation. FOUR years after the global crisis erupted in 2008, organisations such as the International Labour Organisation (ILO) believe that labour markets still have not fully recovered. The world economy is not expected to grow at a sufficient pace over the next couple of years to overcome the crisis. These organisations present some depressing facts: those...

School texts that teach young minds that politics is a contentious and critical but reasonable activity, that it is not merely a set of demands and commands, and that politicians have to be responsive and accountable are naturally disliked by the political class. This is the tone of all the Political Science textbooks of Standards IX-XI brought out after 2006. The nurturing of a culture of critical public opinion seems...

-The Economic Times Petrol car owners in Delhi will get some relief from the recent steep rise in petrol price after the state government decided not to levy value added tax on the price hike announced by the oil marketing companies on last Wednesday. Tobacco products will get costlier, court fee will increase and circle rates for property are expected to rise resulting in steeper stamp duty on property transactions. Public transport...

German drugmaker Bayer AG has demanded the withdrawal of the country's first compulsory licence given to Natco Pharma, arguing that a three-fourth reduction in the price of the anti-cancer drug by another Indian firm has made the permit redundant and its patent itself is vulnerable to being revoked. In March, India allowed Natco Pharma to legally make and sell a low-cost version of cancer drug Nexavar at 3% of the original...